10/2/2024-Unusual Options Activity In Lufax Holding Ltd (LU)
$LU-Bullish flow detected in Lufax Holdings with 6917 calls trading, or 7x the recent avg daily call volume in the name. The OCT 18th 4.50 Calls are being bought at .25-.30
Similar Posts
8/12/2024-Unusual Options Activity In COP
ConocoPhillips engages in the exploration, production, transportation and marketing of crude oil, bitumen, natural gas, natural gas liquids and liquefied.
Unusual Options Activity In Uber Inc (UBER)
11141 $UBER MAY 16th 2025 55.00 PUTS BOUGHT@ 0.98 vs Open Interest of 543 for a total of $1091818 on the BEAR side
9/25/2024-Unusual Options Activity In Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. (CAPR) is a biotechnology company that develops cell and exosome-based therapeutics for treating and preventing rare diseases.
9/18/2023-Unusual Options Activity In LCID
Lucid Group, Inc. is an American manufacturer of electric luxury sports cars and grand tourers headquartered in Newark, California. Lucid vehicles are designed in California and manufactured at Lucid’s factory in Arizona. The company was founded in 2007
9/20/2023-Unusual Options Activity In VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
5/10/2023-Unusual Options Activity In U
Unity Software Inc. operates a platform that provides real-time 3D development tools and services. Its platform provides software solutions to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The company serves enterprises, mid-market companies, and government and non-profit institutions; mid-sized, small, and independent businesses; and individuals across various industries
